The TRK-T3 oncoprotein, isolated from a human papillary thyroid tumor, arises from the fusion between the N-terminal domain of the TFG gene and the tyrosine kinase domain of the NTRK1 receptor. The 68 kDa TRK-T3 oncoprotein displays a constitutive tyrosine kinase activity resulting in its capability to transform NIH3T3 cells. The TFG portion of TRK-T3 contains a coiled-coil domain, which mediates protein oligomerization essential for the oncogene constitutive activation, and several consensus sites for protein interaction. In this study, we investigate the role of TFG sequences outside the coiledcoil domain on TRK-T3 activation, We constructed four mutants carrying different deletions of TFG sequences and expressed them in mammalian cells. By performing biochemical and biological assays we demonstrated that all the deleted regions are required for TRK-T3 activation, as they are involved in different mechanisms such as protein processing, formation of stable and/or functional complexes, and possible interaction with other proteins. By constructing site-specific mutants, we demonstrated a crucial role for a PB1 domain and a considerable contribution of an SH2-binding motif in TRK-T3 oncogenic activation. This work establishes an important role for TFG sequences outside the coiled-coil domain in the activation of the thyroid TRK-T3 oncogene.
Introduction
TRK oncogenes, created by structural rearrangements of the NTRK1/NGF receptor gene (Kaplan et al., 1991; Klein et al., 1991) , are associated with a consistent fraction of human papillary thyroid carcinoma. The rearrangements produce chimeric proteins containing the NTRK1 tyrosine kinase domain preceded by sequences from different activating genes (Pierotti et al., 1996) . Several thyroid TRK oncogenes have been isolated in our laboratory and named TRK, TRK-T1, TRK-T2 and TRK-T3. TRK oncogene is activated by TPM3, encoding the nonmuscle tropomyosin (MartinZanca et al., 1986) ; TRK-T1 and TRK-T2 are both activated by TPR gene, encoding a filamentous protein of the nuclear pore complex (Byrd et al., 1994) ; in TRK-T3 oncogene, the activating portion is contributed by TFG, a novel gene on chromosome 3 encoding a protein of yet unknown function (Greco et al., 1995) . All the activating sequences contain dimerization/oligomerization domains playing a crucial role in oncogenic activation by inducing constitutive, ligand-independent tyrosine kinase activity. Analysis of signal transduction demonstrated that Shc is activated by TRK oncoproteins and therefore capable to recruit Grb2 (Borrello et al., 1994) . We have more recently also determined the activation of FRS2, FRS3, PLCg, ERK1/2 and JNK MAP kinases in cells transformed by TRK-T3 (Greco et al., manuscript in preparation) , as well as the recruitment of IRS1 and IRS2 by TRK-T1 oncoprotein (Miranda et al., 2001) .
The thyroid TRK-T3 oncogene encodes a cytoplasmic protein made of 593 amino acids, 193 of which are contributed by TFG (TRK Fused Gene), a novel gene first discovered in the rearranged form, encoding a protein whose major characteristic is the presence of a coiled-coil domain (Greco et al., 1995) . Recently, the normal TFG counterpart was cloned and characterized. TFG gene is ubiquitously expressed in human adult tissues and it is conserved among several species, including Caenorhabditis elegans. In addition to the coiled-coil domain, the TFG protein also contains putative phosphorylation sites for PKC and CK2, glycosylation sites, as well SH2-and SH3-binding sites (Mencinger et al., 1997) . Several of these sites are identical in TFG proteins from different species, indicating that the protein might be involved in basic cell processes (Mencinger and Aman, 1999) . Interestingly, most of these sites are present in the TFG portion contained in TRK-T3.
The coiled-coil structural motif comprises two or more right-handed a-helices wrapped around each other with a small, left-handed super helical twist. This domain confers to the proteins the capability to fold into coiled-coils, thus mediating oligomerization (Lupas et al., 1991; Lupas, 1996) . Recent studies based on gel filtration chromatography have shown that proteins bearing coiled-coil domains form complexes containing a variable molecule number, ranging from two to six (Matthews et al., 2001) . Coiled-coil domains are present in almost all the sequences activating oncogenes derived from receptor and nonreceptor tyrosine kinases (Rodrigues and Park, 1994) , and their importance in mediating oligomerization leading to constitutive activation has been documented in several cases. These include the MET (Rodrigues and Park, 1993) , the RET/ PTC2 (Durick et al., 1995) , the RET/PTC 1 (Tong et al., 1997) , the TRK-T3 (Greco et al., 1998) , the RET/PTC3 (Monaco et al., 2001) , the Bcr-Abl (McWhirter et al., 1993) and the PML-RAR (Grignani et al., 1999) oncogenes. However, also other regions, different from the coiled-coil domain, might be important for oncoprotein activation. This has been demonstrated for BcrAbl, whose activation requires also a region containing an SH2 domain (McWhirter et al., 1993) , and for TRK-T3, whose transforming activity requires the N-terminal region of TFG (Greco et al., 1998) .
The TFG portion contained in TRK-T3 oncoprotein can be divided into three regions: the N-terminal region (aa 1-96); the coiled-coil domain (aa 97-124) ; the region between the coiled-coil domain and the junction to NTRK1 (aa 125-193) . In a previous work, we have investigated the contribution of TFG coiled-coil domain to TRK-T3 oncogenic activation. By constructing several mutants, we have shown that the TRK-T3 activity depends on oligomerization mediated by the coiled-coil domain. However, as mentioned above, we have also shown that the TFG N-terminal portion, although not interfering with protein self-association, is required for TRK-T3 fully transforming activity (Greco et al., 1998) , suggesting that the regions outside the coiled-coil domain are also important for oncogenic activation.
In the present work, we have further extended this concept by investigating the role of TFG regions outside the coiled-coil domain in TRK-T3 oncogenic activity. This issue is particularly interesting, based on the evidence that TFG contains a single coiled-coil domain, but also displays consensus sites for interaction with other proteins. This raises the question whether or not a coiled-coil domain is sufficient to activate RTK oncogenes. We have constructed four deletion mutants, lacking different portions of TFG sequences outside the coiled-coil domain, and we have assayed their biochemical and biological activities. We provide evidence that the different deletions interfere with protein activation, processing and capability to form functional complexes. To unveil the specific TFG elements responsible for the TRK-T3 regulation, we abrogated consensus sites for protein interaction such as PB1, SH2-and SH3-binding motifs. Our data showed that the PB1 and SH2-binding motifs give an important contribution to TRK-T3 oncogenic activation, whereas the role of the SH3-binding domain requires further investigations. On the whole, our results clearly demonstrate that TFG activating sequences regulate the TRK-T3 biological activity not only by promoting its constitutive oligomerization.
Results

Construction and biochemical analysis of TRK-T3 deletion mutants
To define the role of the TFG regions outside the coiledcoil domain in TRK-T3 oncogenic activation, we have constructed the four deletion mutants shown in Figure 1 . The mutants were constructed by PCR amplification of TRK-T3-specific regions, and in all of them the TFG initiation codon was maintained (see Materials and methods). The T3/L1 mutant, already analysed in a previous study (Greco et al., 1998) , carries the deletion of the TFG portion preceding the coiled-coil domain; in T3/L2, the sequences preceding and following the coiled-coil motif have been removed; T3/L3 carries a small N-terminal deletion (aa 2-27); in T3/L4 the region following the coiled-coil domain has been removed. The mutants were inserted into the pIRESneo bicistronic expression vector, which carries the neomycin resistance gene as selectable marker.
TRK-T3 constructs were transiently transfected into 293T cells, and cell extracts were immunoprecipitated with anti-TRK antibodies. Western blot analysis with antiphosphotyrosine and anti-TRK antibodies was performed ( Figure 2a ). All the mutants expressed Figure 1 Schematic representation of TRK-T3 constructs used in this study. The portions contributed by TFG and NTRK1 are shown. The coiled-coil (CC), transmembrane (TM) and tyrosine kinase (TK) domains are indicated. Putative phosphorylation sites for PKC and CK2 are indicated with circles and 'v', respectively. Asterisks indicate the glycosylation site. SH2-and SH3-binding motifs are indicated by empty circles and arrowheads, respectively. The PB1 domain is indicated by a dotted underline. Tyrosine residues involved in Shc and FRS2 interaction (Y291), PLCg interaction (Y586), and tyrosines of the activation loop (Y470, Y475 and Y476) are indicated. The structure of the wild-type TRK-T3 protein (T3/WT) is shown at the top. In the mutated proteins the deleted regions are indicated by bridging lines Mechanism of activation of TRK-T3 oncogene E Roccato et al phosphorylated proteins whose molecular weight was estimated as 68 kDa for T3/WT, 55 kDa for T3/L1, 45 kDa for T3/L2, 63 kDa for T3/L3 and 53 kDa for T3/ L4. It is important to note that T3/L4 presented an electrophoretic migration faster than T3/L1, although it carries a shorter deletion; this discrepancy might be related to the effect of deletion on protein structure. With respect to tyrosyl phosphorylation, it was reduced in T3/L1 and T3/L3, and drastically reduced in T3/L2; whereas the T3/L4 mutant showed a phosphorylation level slightly increased with respect to wild type. We next analysed the effect of TFG deletions on TRK-T3 ability to recruit several signal transducers, namely Shc, PLCg and FRS2 (Figure 2a) . Hybridization of PLCg and Shc immunocomplexes with antiphosphotyrosine antibodies showed that all the TRK-T3 proteins co-precipitate with the two adaptors. PLCg and Shc were phosphorylated, and the extent of activation correlated with the level of TRK-T3 proteins phosphorylation. Similarly, pull-down experiments with GST-FRS2(PTB) fusion protein, followed by Western blot analysis with antiphosphotyrosine antibodies, showed that the TRK-T3 mutated proteins retain the capability to activate FRS2, although to different extents. In particular, the T3/L3 protein, slightly visible in Figure 2a (last panel), was clearly Altogether these results show that TRK-T3 mutants retain the capability to recruit/activate PLCg, Shc and FRS2 signal transducers.
To determine the effect of TFG deletions on TRK-T3 intrinsic kinase activity, we performed immunokinase assay (Figure 2b ). Cell extracts from 293T cells transfected with TRK-T3 wild-type or deleted mutants were immunoprecipitated with anti-TRK antibody. The immunocomplexes were incubated with [g-32 P]ATP in the presence of exogenous substrate myelin basic protein (MBP), or subjected to Western blot hybridization with anti-TRK antibodies, to determine the protein level. The quantification of relative kinase activity resulted from the ratio between the TRK-T3 autophosphorylation level with respect to protein expression is shown in the bar graph. Autokinase activity was reduced by 30% in T3/L1 and T3/L3, and was almost undetectable for T3/ L2, whereas it was increased in T3/L4 (Figure 2b ). Similar results were obtained analysing the kinase activity of TRK-T3 proteins on the exogenous substrate MBP (data not shown). The differences in kinase activity are comparable to those in steady-state phosphorylation shown in Figure 2a .
By immunofluorescence of transiently transfected NIH3T3 cells, we investigated the cellular localization of mutated TRK-T3 proteins. All of them showed cytoplasmic localization, similarly to the wild type (Figure 3a) . Interestingly, T3/L2-expressing cells showed dispersed punctate cytoplasmic distribution concentrate in visible granules. This is reminiscent of aggresomes, intracellular structures formed by the aggregation of misfolded, insoluble proteins (Johnston et al., 1998) , and suggests that the T3/L2 mutation might interfere with the oncoprotein processing. Indeed, Western blot analysis of transiently transfected 293T cells showed that T3/L2 is present in both soluble and insoluble fractions, but slightly more abundant in the insoluble one, at variance of T3/WT and T3/L1 proteins ( Figure 3b ). 
Self-association and complex formation of wild-type and deleted TRK-T3 oncoproteins
The TFG portion of TRK-T3 contains a coiled-coil domain driving the oncoprotein self-association important for full oncogenic activity. To determine if the regions outside the coiled-coil domain contribute to the TRK-T3 self-association, we performed in vitro binding assays with a GST/T3 fusion protein, made of the glutathione-S-transferase fused in frame with TRK-T3 protein (from aa 23 to C-terminus) (Greco et al., 1998) . The mutated proteins were translated in vitro in the presence of 35 S-labeled methionine ( Figure 4a , left panel). Samples containing approximately the same amount of each TRK-T3 protein were incubated with the GST/T3 fusion protein conjugated to glutathionesepharose. All the labeled TRK-T3 proteins were eluted from the GST complexes ( Figure 4a , right panel), indicating that the capability to associate in vitro with TRK-T3 wild type was not abrogated by the deletions.
Computer-assisted analysis with the MultiCoil score program indicated that the TFG coiled-coil domain has high probability to fold into trimers (data not shown). In a previous work, based on the sedimentation profile on a sucrose density gradient, we have demonstrated that TRK-T3 forms high molecular weight complexes (>220 kDa) (Greco et al., 1995) . To better define TRK-T3 complexes we performed HPLC size-exclusion chromatography (Superdex 200 HR10/30; Pharmacia). Extracts prepared from 293T cells expressing the different TRK-T3 constructs were fractioned by sizeexclusion chromatography, and samples of each fraction were immunoblotted with anti-TRK antibodies ( Figure 4b ). The T3/WT protein was eluted in fractions corresponding to high molecular masses of approximately 400-480 kDa. Since the molecular weight of monomer TRK-T3 wild type is 68 kDa, such complexes might contain six molecules; alternatively, they might contain other proteins in addition to TRK-T3. Although the complex composition remains to be determined, the relevance of this study is the demonstration that the wild-type TRK-T3 protein is part of the high molecular weight complexes. Based on these evidences we next investigated the effect of mutations on complex formation by performing size-exclusion chromatography and Western blot analysis with anti-TRK antibodies for all the mutants, as described above ( Figure 4b ). T3/L1 protein showed a peak at 400-480 kDa, but was also detected in fractions corresponding to lower molecular weights. T3/L2 protein, which is Figure 4 Self-association and complex formation of wild-type and mutated TRK-T3 proteins, (a) In vitro self-association assay. cDNA constructs were transcribed and translated in vitro as described in Materials and methods. The in vitro translated proteins were electrophoresed before (left) and after (right) incubation with the sepharose-bound GST/T3 fusion protein (see Materials and methods), (b) Lysates of 293T cells expressing TRK-T3 proteins were fractionated by size-exclusion chromatography, and samples from fractions were resolved by SDS-PAGE and immunoblotted using anti-TRK antibodies. The TRK-T3 wild-type complexes elute in fractions 18 and 19, which correspond to molecular masses of approximately 480-400 kDa. The fraction numbers are indicated. The fractions corresponding to molecular size standards thyroglobulin (670 kDa), gamma globulin (158 kDa), and ovalbumin (44 kDa) are indicated. The molecular weight of TRK-T3 proteins is indicated Mechanism of activation of TRK-T3 oncogene E Roccato et al definitely smaller than wild-type, was eluted in the same high molecular weight fractions as the wild-type protein. This pattern is compatible with the formation of abnormal complexes, containing either an aberrant number of TRK-T3 molecules or proteins not recruited by wild-type TRK-T3, such as proteins of the degradation pathway. The T3/L3 protein, with molecular weight similar to the wild type (63 kDa), showed a more distributed elution pattern, ranging from 70 to 480 kDa, indicating a reduced capability to form functional complexes. T3/L4 protein showed an elution pattern similar to T3/WT and T3/L1, indicating no effect of the deletion in complex formations.
Differentiating activity is retained by TRK-T3 deletion mutants
Similarly to the NGF-stimulated NTRK1 receptor, the TRK oncogenes are capable of inducing differentiation of PC12 cells. To test the effect of TFG deletions on this activity, PC12 cells were cotransfected with the different TRK-T3 constructs and the VGF8-luc reporter plasmid: the latter is made of the luciferase reporter gene driven by the promoter of the vgf, a gene induced by NGF and considered a differentiation marker (Possenti et al., 1992; Canu et al., 1997) . All the mutated proteins were able to induce formation of neurites (data not shown). However, PC12 cells expressing T3/L2 and T3/L3 proteins displayed shorter neurites with respect to T3/ WT-, T3/L1-and T3/L4-expressing cells. To quantify the differentiating activity, we measured the capability of TRK-T3 proteins to induce the expression of the VGF8-luc reporter gene by performing luciferase assays on the extracts of cotransfected PC12 cells described above. As shown in Figure 5 , the luciferase activity was slightly increased in cells expressing T3/L1; in cells transfected with T3/L2 and T3/L3 constructs, a decrease of luciferase activity (54 and 45%, respectively) was observed; a minor reduction (20%) was detected in cells expressing T3/L4. These data suggest that all TRK-T3 deleted mutants retain the capability to promote PC12 cells differentiation, although to a different extent.
Transforming activity of mutated TRK-T3 proteins
To determine the effect of TFG deletions on TRK-T3 oncogenic activity, we analysed the capability of TRK-T3 mutants to transform NIH3T3 cells. Transfected cells were selected in the presence of G418, to determine the transfection efficiency, or in 5% serum medium, to determine the transforming activity. The results of a representative focus formation experiment are reported in Table 1 . The T3/L1 mutant induced foci with efficiency reduced by 80% with respect to the wild type. In a previous study, with a different expression vector, the T3/L1 mutant failed to induce foci formation (Greco et al., 1998) ; this discrepancy is most likely related to differences in expression level, as it will be discussed later. On the contrary, no transforming activity was detected for mutants T3/L2, T3/L3 and T3/L4. These data suggest that the regions outside the coiled-coil domain may have a crucial role in TRK-T3 oncoprotein transforming activity, although they abrogate neither the constitutive oncogene activation, nor its differentiating capability.
We have previously observed that the expression of a transfected gene carried by a mammalian expression vector increases if transfected cells are cultured for 10-15 days in the presence of the antibiotic whose resistance gene is on the same vector (Roccato et al., 2002) . We were interested in determining whether the TRK-T3 mutants transforming activity might be modulated by the oncoprotein expression level. To this aim, transfected NIH3T3 cells were first selected in a medium containing G418 for 2 weeks, then shifted to 5% serum medium, and scored for foci 2 weeks later (see Materials and methods). As reported in Table 2 (third column), by applying G418 preselection foci were induced not only by T3/WT and T3/L1, but also by mutants T3/L2, T3/ L3 and T3/L4, which were scored negative in the previous analysis (Tables 1 and 2 , first column). On the contrary, no foci arose in NIH3T3 cells transfected with the empty vector, and no recovery of transforming activity was observed for mutants T3/L2. T3/L3 and T3/ L4 by simply extending to 4 weeks the selection time in 5% serum, without G418 preselection (Table 2 , second column). Altogether, these data suggest that transforming activity is not completely abrogated in the TRK-T3 mutants since it can be recovered by enhancing the TRK-T3 proteins expression level. Thus, the achievement of a threshold oncoprotein level is necessary to induce the transformed phenotype. In keeping with these results, NIH3T3 clones, selected and cultured in the presence of G418, and expressing considerable amount of TRK-T3 mutated proteins, displayed trans- In fact, they were spindle shaped, less adherent than untransfected NIH3T3 cells, and showed a complete disorganization of the actin stress fibers (data not shown).
To get more insight into the transforming potential of the TRK-T3 mutants, we analysed their capability to induce tumor formation in vivo. The NIH3T3 cell lines expressing TRK-T3 proteins and showing transformed phenotype described above were injected into nude mice. For each cell line, two different doses (10 4 and 10 3 cells) were used. By injecting 10 4 cells per animal, all the cell lines induced tumor formation in 3/3 mice, except T3/L2, which induced tumor formation in 2/3 mice. They differed in the latency, which was delayed of 3 days for T3/L1, 5 days for T3/L3, 13 days for T3/L4 and 16 days for T3/L2 with respect to T3/WT (Table 3) . The difference in tumorigenicity was emphasized by injecting 10 3 cells: T3/L2 cell line failed to induce tumor formation, whereas the other cell lines induced tumor formation in 3/3 mice, with latency longer than wild type. The tumor weight rate was comparable for all the cell lines. Since no differences in growth rate were detected by in vitro proliferation assay (data not shown), the differences in tumor latency were most likely related to the intrinsic tumorigenicity of the cell lines. These data indicate that all the TFG deletions interfere with TRK-T3 tumorigenicity, in agreement with the in vitro NIH3T3 transformation results.
Construction and analysis of site-specific TRK-T3 mutants
The data reported in the previous paragraphs showed that the transforming activity was reduced in all the TRK-T3 deletion mutants. Whereas the defects of T3/ L2 and T3/L3 mutants can be ascribed to impairments of processing and complex formation, respectively, such properties are unaffected in T3/L1 and T3/L4 mutants. Interestingly, some important sites, suggesting possible interaction with other proteins, are present in the TFG region. A computer-assisted search with the SMART program revealed the presence of a PB1 domain (aa 10-91), presumably involved in protein-protein interaction . Such domain is deleted completely or partially in T3/L1 and T3/L3 mutant, respectively. Moreover, a putative SH2-binding site is removed by the T3/L1 deletion, and a putative SH3-binding site is contiguous to the coiled-coil domain (Figure 1 ). To determine the role of these specific domains in TRK-T3 oncogenic activation, we constructed three site-specific mutants (Figure 6a ). T3/K14A carries the mutation of the conserved Lys residue within PB1 domain; such (NIH3T3 cells were transfected with wild-type or mutated TRK-T3 plasmids or empty vector (pIRES), and a focus formation assay was performed. Number of foci, number of G418 resistant colonies and relative transforming activity are shown) 
NIH3T3-transfected cells were selected in 5% serum medium for 2 or 4 weeks (first and second column, respectively), or selected in G418 for 2 weeks, then shifted in 5% serum medium for other 2 weeks (third column). Afterwards, selection plates were scored for foci. + and À indicate the foci presence and absence, respectively Mechanism of activation of TRK-T3 oncogene E Roccato et al residue in Bem1p has been shown to be important for the interaction with the cognate PC domain of Cdc24p Terasawa et al., 2001) . T3/Y33F carries the mutation of the Tyr residue within the putative SH2-binding domain. In T3/DPro the putative SH3-recognition motif (PPGEPGP) was deleted. The mutants were constructed by site-directed mutagenesis using the TRK-T3 wild-type cDNA inserted into the pIRESneo expression vector as template (see Materials and methods). The mutated constructs were transiently transfected into 293T cells; Western blot analysis showed that they are properly expressed and phosphorylated (Figure 6b ). The effect of the site-specific mutations on TRK-T3 activity was investigated by NIH3T3 transfection/focus formation assay. The results are reported in Figure 6c . T3/K14A mutant displayed a very low transforming activity, comparable to the background. T3/Y33F transforming activity was reduced by 80% with respect to wild type and equivalent to T3/L1. T3/DPro induced transformation with efficiency slightly reduced with respect to wild type. These data demonstrate that the mutation of the specific interaction motifs analysed affects strongly or at least in part the TRK-T3 oncogenic activation, suggesting that proteins recruited by TFG may be involved in this process.
Discussion
The thyroid TRK-T3 oncoprotein is composed of the NTRK1 tyrosine kinase domain fused in frame with the N-terminal portion of TFG, a novel protein containing a coiled-coil domain, putative phosphorylation sites for PKC and CK2, SH2-and SH3-binding consensus sites (Mencinger et al., 1997) and a PB1 motif identified in this study.
Coiled-coil domains promote oncoproteins multimerization that triggers constitutive transautophosphorylation and oncogenic activation. We have previously shown that the TFG coiled-coil domain mediates the capability of TRK-T3 to form complexes and therefore is essential for its oncogenic activation (Greco et al., 1998) .
An attractive hypothesis is the possibility that fusion partners may contribute to the activation of rearranged tyrosine kinase oncogenes with additional functions, The TFG coiled-coil domain is predicted to fold into trimers, and we have previously shown that it triggers TRK-T3 multimerization (Greco et al., 1998) . By removing TFG sequences outside the coiled-coil domain, TRK-T3 oncogene maintains its in vitro selfassociation capability, as demonstrated by pull-down experiments with the GST/T3 fusion protein. By sizeexclusion chromatography we have determined that wild-type TRK-T3 forms in vivo high molecular weight complexes of approximately 400-480 kDa. Considering that the molecular weight of TRK-T3 monomer is 68 kDa, such complexes would include six oncoprotein molecules. This hexameric organization might result from the assembly of two TRK-T3 trimers, as described for RSV F protein (Matthews et al., 2001) . However, the complexes might contain other proteins, in addition to TRK-T3. We excluded the presence of adaptor proteins for the following reasons: (i) the same chromatography pattern of T3/WT was obtained for a TRK-T3 kinasedead mutant or T3/WT treated with the specific inhibitor K252a (data not shown); (ii) Western blot analysis failed to detect Shc and PLCg in the chromatography's fractions containing TRK-T3, whereas Shc was detected in low molecular weight fractions (data not shown). The complexes might also include the wild-type TFG protein; however, given the high expression level of TRK-T3, the wild-type TFG contribution to the complex formation might be irrelevant.
The chromatography patterns of the mutated proteins showed that T3/L1 and T3/L4 proteins form complexes similar to T3/WT, with a prevalent distribution in fractions of high molecular weight; T3/L3, with a molecular weight similar to the wild type, shows a large distribution ranging from 70 to 480 kDa and corresponding to different status of aggregation. This indicates that the deleted sequences in this mutant interfere with the formation and/or stability of functional TRK-T3 complexes. The T3/L2 protein is recovered in the same fractions as the wild type, although it is smaller and, presumably, unable to interact with putative proteins recruited by the deleted sequences. The T3/L2 sedimentation profile may be due either to the formation of homocomplexes with an aberrant molecule number, or to the presence of proteins not recruited by wild-type TRK-T3, such as proteins of the degradation machinery.
Analysis of TRK-T3 mutants biological activity showed apparently different results in PC12 and NIH3T3 cells. In fact, by transfection of PC12 cells we showed that all the mutants maintain the differentiating activity, although a reduction for T3/L2 and T3/L3 was observed. On the contrary, NIH3T3 transfection experiments showed that the T3/L1 capability to form foci was reduced by 80% with respect to the wild type, whereas no transforming capability was observed for the other mutants. However, we detected transforming activity of TRK-T3 mutants by enhancing the protein expression level with G418 preselection of transfected NIH3T3 cells before foci selection. This procedure allows the achievement of a threshold oncoprotein level necessary to induce the transformed phenotype. Transformation induced by the mutated proteins was morphologically indistinguishable from the wild type. However, NIH3T3 cell lines transformed by TRK-T3 mutants differed from wild type in in vivo tumorigenicity, since they showed a significant delay in tumor formation.
TFG contains several putative sites for interaction with other proteins. The presence of SH2-and SH3-binding motifs has been previously reported (Mencinger and Aman, 1999) . A computer analysis revealed the presence of a putative PB1 domain, a novel protein module capable of binding to target proteins that contain PC motifs . To unveil the elements playing a crucial role in TRK-T3 oncogenic activation, we constructed mutants in which the above mentioned domains, presumably involved in protein interaction, were ablated. We constructed three mutants carrying, respectively, the mutation of the Lys residue of the PB1 domain shown to be important for the binding of Bem1p to the PC domain of Cdc24p; the mutation of the Tyr residue within the SH2-binding domain; and the deletion of the SH3-binding domain. Biological analysis indicated that the PB1 and SH2-binding domains give an important contribution to TRK-T3 biological activity. PB1 domain seems to be indispensable, since its mutation completely abrogates TRK-T3 transforming activity. This suggests that interaction with protein recruited by the PB1 domain plays a crucial role. On the other hand, the mutation of the SH2-binding motif significantly reduced the oncogenic activity, indicating an important role for such domain. Interestingly, the SH2-binding motif is specific for the tyrosine phosphatase SHP-1, proposed to play a regulatory role in many cellular signaling processes (Fujioka et al., 1996; Mencinger and Aman, 1999) . With respect to the SH3-binding domain, the slight reduction of transforming activity observed in this study does not allow speculating about its precise role in TRK-T3 activation; this topic will require more investigations.
In this paper, we have shown that the TFG coiled-coil domain is necessary, but not sufficient for the activation of the thyroid TRK-T3 oncogene. Using both deletion and site-specific mutants we have demonstrated that the regions outside the coiled-coil domain play a crucial role in TRK-T3 transforming activity. In fact, such sequences regulate protein processing, complex formation and possible interaction with other proteins. This latter possibility is strongly supported by the constructs carrying mutations of the PB1 and SH2-binding domains, in which a single amino acid change strongly affected the transforming activity. The search for proteins interacting with PB1 and SH2 domains and the analysis of such interactions, as well as the analysis of other consensus sites will help in elucidating the mechanisms by which the TFG sequences regulate TRK-T3 activation.
Materials and methods
Plasmid construction
The TRK-T3 cDNA inserted into the pRC/CMV expression vector previously reported (Greco et al., 1995) was excised by HindIII/XbaI digestion, blunted, and inserted into the pIRESneo vector linearized with NotI and blunted, to produce T3/ WT. The T3/L1 mutant was constructed by PCR amplification (Greco et al., 1998) . The oligonucleotides utilized were AG3046 (5 0 -ATC CTG GAG TCC ACC ATG AAT GGC CAG CCA AGA CC-3 0 ) and AG2964 (5 0 -TTT TTT TTC AAG GGA TAA TAA ATA TAA TTG CT-3 0 ). The amplified 1740 bp fragment was inserted into pGEMT plasmid vector, subjected to nucleotide sequence, excised by NotI and ApaI/ blunt digestion and introduced into pIRESneo expression vector linearized with NotI and BamHI/blunt. The resulting construct encodes the T3/L1 protein in which the TFG initiation codon is followed by Asn 91.
The T3/L2 mutant was constructed by PCR amplification followed by DNA ligation. The 5 0 moiety was amplified using oligonucleotides AG3046 (5 0 -ATC CTG GAG TCC ACC ATG AAT GGC CAG CCA AGA CC-3 0 ) and AG3047 (5 0 -TAA TAG GAT CCA ATA TTG GTG GAA GGT-3 0 ). The 3 0 moiety was amplified using oligonucleotides AG3048 (5 0 -ATT ATG GAT CCC CGG TGG-3 0 ) and AG2964 (5 0 -TTT TTT TTC AAG GGA TAA TAA ATA TAA TTG CT-3 0 ). The amplified fragments of 153 and 1389 bp, respectively, were cloned into pGEMT vector to produce the pGL2/5 0 and pGL2/3 0 plasmids, respectively, and subjected to nucleotide sequence. The 5 0 fragment was excised from plasmid pGL2/5 0 by BamHI/NotI digestion and was inserted into the pGL2/3 0 plasmid linearized with the same restriction enzymes. The resulting plasmid pGL2 carried the deletion of all TFG sequence except the coiled-coil domain. After nucleotide sequence, the deleted TRK-T3 cDNA was excised from plasmid pGL2 by NotI digestion and inserted into the pIRESneo vector linearized with the same restriction enzymes, to produce T3/L2. The T3/L3 mutant was constructed by PCR amplification. The oligonucleotides utilized were AG3514 (5 0 -ATC CTG GAG TCC ACC ATG AAT GAA GAT ATT ACT-3 0 ) and AG2964 (5 0 -TTT TTT TTC AAG GGA TAA TAA ATA TAA TTG CT-3 0 ). The amplified 1929 bp fragment was inserted into pGEMT plasmid vector, subjected to nucleotide sequence, excised by NotI and ApaI/blunt digestion, and introduced into pIRESneo expression vector linearized with NotI and BamHI/blunt. The resulting construct encodes the T3/L3 protein in which the TFG initiation codon is followed by Asn 28.
The T3/L4 mutant was constructed by PCR amplification followed by DNA ligation. The 5 0 moiety was amplified using oligonucleotides AG3055 (5 0 -ATC CTG GAG TCC ACC ATG-3 0 ) and AG3047 (5 0 -TAA TAG GAT CCA ATA TTG GTG GAA GGT-3 0 ). The 3 0 moiety was amplified using oligonucleotides AG3048 (5 0 -ATT ATG GAT CCC CGG TGG-3 0 ) and AG2964 (5 0 -TTT TTT TTC AAG GGA TAA TAA ATA TAA TTG CT-3 0 ). The amplified fragments of 423 and 1388 bp, were cloned into pGEMT vector to produce the pGL4/5 0 and pGL4/3 0 plasmids, respectively, and subjected to nucleotide sequence. The 5 0 fragment was excised from plasmid pGL4/5 0 by BamHI and SalI/blunt digestion and was inserted into the pGL4/3 0 plasmid after linearizing with BamHI and SphI/blunt. The resulting plasmid pGL4 carried the deletion of nucleotides 424-621. After nucleotide sequence the deleted TRK-T3 cDNA was excised from plasmid pGL4 by ApaI/NotI digestion, blunted, and inserted into the pIRESneo vector linearized with EcoRV, to produce T3/L4.
All the site-specific mutants were constructed by the Gene Editort in Vitro Site-directed Mutagenesis System (Promega), according to the manufacturer's instructions, using as template the T3/WT plasmid. T3/K14A, carrying the mutation of the Lysine 14 to Alanine, was constructed using the oligonucleotide 5 0 -AAGCTAATCGTCGCAGCTCAACTTGGG-3 0 (the mutated nucleotides are indicated in boldface type). T3/Y33F, carrying the mutation of the Tyrosine 33 to Phenylalanine, was constructed using the oligonucleotide 5 0 -GATATTACTTTT-GATGAATTAG-3 0 (the mutated nucleotides is indicated in boldface type). T3/nPro, carrying the deletion of the SH3-binding motif (nucleotides 391-411), was constructed using the oligonucleotide 5 0 -TTGGATAGCTTGGAATCCACCAA-TATTCC-3 0 . Clones carrying the K14A or Y33F mutations were identified by sequence analysis. In the case of T3/DPro mutant, a fragment spanning the mutation was amplified by PCR. Mutant fragments were identified by faster electrophoretic mobility with respect to wild type, owing to the 21 bases deletion. All of the mutant clones were subjected to nucleotide sequence to exclude possible additional mutations accidentally occurring during the mutagenesis reaction.
The TRK-T3 kinase dead mutant, used as control, carries the mutation of the ATP binding site Lysine 339 to Alanine (Greco et al., 1998) .
The VGF8-luc is a reporter plasmid made of vgf promoter sequence fused to the luciferase reporter gene (a kind gift from Dr R Possenti).
The pRL-CMV vector, containing the coding region of the Renilla luciferase (RL) gene, was provided by Promega.
Cell culture and transfection
Mouse NIH3T3 fibroblasts were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% calf serum; human kidney 293T cells were cultured in DMEM supplemented with 10% fetal calf serum. PC12 cells were grown in RPMI-1640 medium supplemented with 5% fetal calf serum and 10% horse serum.
The NIH3T3 cells (8 Â 10 4 /60 mm plate) were transfected by the CaPO 4 method using 250 ng of expression plasmid DNA together with 15 mg of mouse carrier DNA. Transfected cells were selected in DMEM supplemented with 10% serum in the presence of G418 antibiotic (400 mg/ml), to determine the transfection efficiency, and in medium containing 5% serum to determine the transforming activity. In some experiments, a G418 preselection was applied. Transfected NIH3T3 cells were firstly selected for 2 weeks in DMEM supplemented with 10% serum in the presence of G418; subconfluent cell cultures were then shifted to a medium containing 5% serum for additional 2 weeks. At the end of selection, G418-resistant colonies and transformed foci were either fixed or isolated for further studies.
The 293T cells were transiently transfected using the CaPO 4 method with 5 mg of plasmid DNA. One day after transfection, cells were kept in 10% serum medium for 6-7 h, serum-starved 20 h in DMEM containing 0.5% FCS, and then processed for protein extraction.
PC12 cells were transfected using Cellfectin (Life Technologies, Inc.). Cells (2 Â 10 5 ) were seeded on collagen-coated 12-multiwell plates and transfected with 50 ng of specific plasmid DNA together with 150 ng of VGF8-luc plasmid, 50 ng of pRL-CMV plasmid (Promega) and 350 ng of plasmid carrier DNA. Cells were incubated with the reagent for 7 h and scored for neurites outgrowth 2 days later.
Luciferase activity assay
Both luciferase activities of VGF8-luc and pRL-CMV genes in PC12 cells lysates (5 mg) were measured using the Dualluciferase reporter assay system (Promega), according to the manufacturer's recommendations. Light emission was measured using a TD-20/20 Luminometer.
Immunoprecipitation, pull-down and Western Blot analyses
Cells were lysed with PLCLB buffer (50 mm HEPES, 150 mm NaCl, 10% glycerol, 1% Triton X-100, 1.5 mm MgCl 2 , 1 mm EGTA, 10 mm Na 4 P 2 O 7 , 100 mm NaF) supplemented with aprotinin, pepstatin, leupeptin, PMSF, and Na 3 VO 4 . Insoluble material was recovered by centrifugation at 13 000 g for 15 min and solubilized in 50 ml 10 mm Tris-HCl, 1% SDS for 10 min at room temperature. After addition of 200 ml PLCLB, samples were sonicated for 20 s with a tip sonicator.
One milligram of the cell extracts was precipitated with the appropriated antibodies, or with GST-FRS2(PTB) fusion proteins conjugated to glutathione-sepharose. The precipitates were washed three times with HNTG buffer (20 mm HEPES, 150 mm NaCl, 0.1% Triton X-100, 10% glycerol) and boiled in Laemmli sample buffer. Protein samples were electrophoresed on an 8.5% SDS-PAGE, transferred onto nitrocellulose filters and immunoblotted with the appropriated antibodies. The immunoreactive bands were visualized using horseradish peroxidase-conjugated secondary antibody and enhanced chemiluminescence (Amersham). The anti-TRK and antiPLCg antibodies were from Santa Cruz Biotech., Inc.; the anti-Shc, anti-phosphotyrosine antibodies were from Upstate Biotechnology. Inc.
Immunokinase assay
293T cells transiently expressing wild-type and deleted TRK-T3 proteins were lysed in radioimmune precipitation buffer (RIPA) (20 mm Tris-HCl, pH 7.5, 150 mm NaCl, 5 mm EDTA, 1% NP-40) supplemented with protease inhibitors. TRK-T3 proteins were immunoprecipitated with anti-TRK antibodies, adsorbed on protein A-Sepharose beads, and washed twice with RIPA buffer. One set of immunoprecipitates was washed once with incubation buffer (50 mm HEPES, 20 mm MnCl 2 , 5 mM MgCl 2 , 1 mm dithiothreitol), afterwards the samples were incubated for 10 min at 301C in 50 ml of the same buffer containing 10 mm ATP and [g-32 P]ATP (5000 Ci/mmol; Amersham Biosciences) in the presence of exogenous substrate myelin basic protein (MBP). After washing with RIPA buffer, proteins were eluted and subjected to SDS-PAGE, and the gel was dried. 32 P-labeled proteins were revealed and quantified by using PhosphorImager apparatus (Typhoon 8600, Amersham). A second set of immunoprecipitates was used for protein-level determination by Western blotting with anti-TRK antibodies. Immunoreactive bands were detected by using I25 I-labeled protein A (Amersham) and visualized/ quantified by using PhosphorImager apparatus (Typhoon 8600, Amersham).
Immunofluorescence assay
Transiently transfected NIH3T3 cells were plated on glass coverslips, were fixed with 3% paraformaldehyde plus 2% sucrose, and stained with anti-TRK antibodies (Santa Cruz Biotech.) and Alexa-546-conjugated secondary antibody (1 : 500; Alexa Fluor, Molecular Probes). Stained cells were observed with confocal microscope BioRad Radiance 2100 equipped with HeNe laser 546 nm and mounted on a Nikon Eclipse 300 fitted with a Plan Apo 60 Â /1.4 lens. The images were digitalized at a resolution of 8 bits onto an array of 512 Â 512 pixel.
In vitro translation
The TRK-T3 wild-type and mutated cDNAs cloned into pGEMT vectors were subjected to in vitro transcriptiontranslation using the TNT-coupled reticulocyte lysate system (Promega), according to the manufacturer's specification. The proteins were translated in the presence of 35 S-labeled methionine; reactions were performed in a volume of 25 ml, using 1 mg of plasmid DNA as template.
In vitro binding assay using GST/T3 fusion protein Expression and purification of GST/T3 fusion protein were performed as described elsewhere (Greco et al., 1998) . In vitro translated TRK-T3 proteins were incubated with the glutathione-sepharose-conjugated GST/T3 fusion protein at 41C for 2 h. The bound proteins were eluted from the complexes by boiling in Laemmli buffer and resolved on 8.5% polyacrylamide gel. After fixing in 30% methanol, 7% acetic acid, the gel was treated with 1 m salicylic acid, sodium salt for 30 min and dried. Autoradiography was performed after overnight exposure to hyperfilm.
Size-exclusion chromatography
Nondenatured cell extracts from 293T cells transiently transfected with TRK-T3 wild type or mutants were lysed in 200 ml of NP-40 lysis buffer (1% NP-40, 10% glycerol, 140 mm NaCl, 10 mm Tris) supplemented with the protease inhibitors described above. After 0.45 mm filtration the samples were applied to a size-exclusion column (Superdex 200 HR10/30; Pharmacia) and eluted at a flow rate of 0.5 ml/min. Fractions were collected at 1 min intervals and analysed by Western blot with anti-TRK antibodies.
In vivo studies
Animal studies were reviewed and approved by the Ethics Committee for Animal Experimentation of the Istituto Nazionale Tumori (Milan, Italy) and are in accordance with the guidelines of the UK Coordinating Committee for Cancer Research. Female CD-1 nu/nu mice (8 to 9 weeks old) (Charles River, Calco, Italy) were injected s.c. with NIH3T3-transfected cells; for each animal 10 4 or 10 3 cells in 0.2 ml PBS were used.
Three mice per sample were used for each experiment. Tumor growth of injected animals was assesed by evaluating tumor latency, that is, days to reach 0.1 g, and by monitoring tumor weight (TW) twice a week. Tumor weight in grams was estimated by the formula TW ¼ d 2 Â D/2, where d and D are, respectively, the shortest and longest diameters of the tumor, measured in centimeters.
